Dan Cristian Popescu

Dr. Dan Cristian Popescu


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2025 in Medicina
Verified
Journal Article
Open access
PDF file
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
Mara DiaconuMara Diaconu
Mara Diaconu
DTDiana Tint
Diana Tint
NANechita Alexandru
Nechita Alexandru
Background and Objectives: Risk stratification in acute heart failure (AHF) remains challenging, particularly in settings where biomarker availability is limited. Echocardiography offers valuable hemodynamic insights, but no single parameter fully captures the complexity of biventricular dysfunction and pressure overload. This study aimed to evaluate a novel echocardiographic index (ViRTUE Index–VTI-RVRA-TAPSE Unified Evaluation) integrating a peak systolic gradient between the right ventricle and right atrium (RV-RA gradient), tricuspid annular plane systolic excursion (TAPSE), the velocity–time integral in the left ventricular outflow tract (VTI LVOT), NT-proBNP (N-terminal pro–B-type Natriuretic Peptide) levels, and in-hospital mortality among patients with AHF. Materials and Methods: We retrospectively analyzed 123 patients admitted with AHF. Echocardiographic evaluation at admission included TAPSE, VTI LVOT, and the RV-RA gradient. An index was calculated as RV−RA gradient TAPSE x VTI LVOT. NT-proBNP levels and in-hospital outcomes were recorded. Statistical analysis included correlation, logistic regression, and ROC curve evaluation. Results: The proposed index showed a significant positive correlation with NT-proBNP values (r = 0.543, p < 0.0001) and good discriminative ability for elevated NT-proBNP (AUC = 0.79). It also correlated with in-hospital mortality (r = 0.193, p = 0.032) and showed moderate prognostic performance (AUC = 0.68). Higher index values were associated with greater mortality risk. Conclusions: This novel index, based on standard echocardiographic measurements, reflects both systolic dysfunction and pressure overload in AHF. Its correlation with NT-proBNP and in-hospital mortality highlights its potential as a practical, accessible bedside tool for early risk stratification, particularly when biomarker testing is unavailable or delayed.

22 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
Mara DiaconuMara Diaconu
Mara Diaconu
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
DTDiana Tint
Diana Tint
NANechita Alexandru
Nechita Alexandru
Background and Objectives: Acute heart failure (AHF) has heterogeneous clinical profiles and considerable short-term mortality. Bedside evaluation of congestion and peripheral perfusion may help identify clinically relevant risk groups. This study aimed to evaluate the relationship between a non-invasive congestion–perfusion classification and in-hospital mortality in patients hospitalized with AHF and to explore the prognostic relevance of clinical, biological, and right-heart variables within the phenotypes. Materials and Methods: We performed an observational study that analyzed 790 patients hospitalized with AHF. Patients were classified at presentation into four predefined congestion–perfusion phenotypes: non-congested/preserved perfusion, congested/preserved perfusion, non-congested/impaired perfusion, and congested/impaired perfusion. Congestion was defined using pulmonary and systemic markers, whereas impaired perfusion was defined by the presence of at least two predefined criteria of hypoperfusion. Clinical, biological, and echocardiographic parameters were analyzed according to phenotype and in-hospital mortality. Discriminative performance was evaluated using ROC curve analysis, and logistic regression models were constructed within the congestive phenotypes to investigate the prognostic value of combined clinical and biological markers, with bootstrap internal validation in the combined models. Results: 78 patients died during hospitalization, with different rates across phenotypes; 2.9% in non-congested/preserved perfusion, 3.0% in non-congested/impaired perfusion, 8.0% in congested/preserved perfusion, and 19.5% in congested/impaired perfusion. In congestive phenotypes, several adverse markers were identified. Exploratory combined models demonstrated discriminatory performance in the congested/preserved perfusion phenotype (AUC 0.731) and in the congested/impaired perfusion phenotype (AUC 0.838); bootstrap optimism-corrected AUCs were 0.693 and 0.785, respectively. Right ventricular parameters were more strongly associated with mortality in the congested/impaired perfusion phenotype. LVEF showed limited discrimination within individual phenotypes. Conclusions: The highest in-hospital mortality was observed in the congestive/impaired perfusion phenotype, with a more adverse clinical, biological, and echocardiographic profile. Within the congestive phenotypes, exploratory prognostic marker patterns were partially overlapping, while LVEF showed limited discrimination.

12 December 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
Mara DiaconuMara Diaconu
Mara Diaconu
DTDiana Tint
Diana Tint
NANechita Alexandru
Nechita Alexandru
Background/Objectives: Acute heart failure (AHF) is a heterogeneous syndrome with phenotype-dependent prognosis. NT-proBNP is the reference biomarker, but standard echocardiographic measures (TAPSE, RV–RA gradient, LVOT VTI) offer only partial prognostic insight. The Virtue Index, defined as (RV–RA gradient)/(TAPSE × LVOT VTI), was introduced to integrate right–left ventricular interaction. This study evaluated its clinical and prognostic performance in AHF and its behavior across ejection-fraction phenotypes. Methods: We retrospectively analyzed 222 patients with AHF; complete data for Virtue calculation were available in 168 (99 HFrEF, 69 HFpEF) patients. HFmrEF patients were excluded from subgroup prognostic analyses. Correlation with NT-proBNP was assessed using Spearman testing with bootstrap intervals, and in-hospital mortality prediction was evaluated using ROC analysis with DeLong comparisons. Results: In HFpEF, the Virtue Index correlated moderately with NT-proBNP (ρ = 0.38, p = 0.002) and showed fair prognostic discrimination (AUC 0.704), similar to the RV–RA gradient (0.724) and higher than TAPSE or LVOT VTI. In HFrEF, correlation was weak (ρ = 0.19, p = 0.06) and predictive accuracy was modest (AUC 0.584), while LVOT VTI performed best (AUC 0.700). NT-proBNP outperformed all echocardiographic parameters in both groups. Conclusions: The Virtue Index reflects integrated hemodynamics and shows phenotype-dependent prognostic value in AHF, being more informative in HFpEF than in HFrEF. Although NT-proBNP remained superior, Virtue may complement biomarker-based risk assessment by offering a rapid, bedside estimate of short-term mortality risk.

10 September 2026 in Medicina
Verified
Journal Article
Open access
PDF file
VEVasilica Enache
Vasilica Enache
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
BMBogdan Marcu
Bogdan Marcu
Mara DiaconuMara Diaconu
Mara Diaconu
NANechita Alexandru
Nechita Alexandru
Metabolic syndrome came to the attention of the scientific community several decades ago, and its definition has undergone multiple changes over time. It is currently defined by the coexistence of hypertension, central obesity, dyslipidemia, and impaired glucose metabolism, with insulin resistance, chronic inflammation, and oxidative stress representing important underlying pathophysiological mechanisms. The latter two processes are major promoters of the onset and progression of atherosclerosis. In parallel, many individuals develop metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called non-alcoholic fatty liver disease (NAFLD). Growing evidence indicates that MASLD may interact bidirectionally with cardiovascular, renal, and metabolic dysfunction and may contribute to cardiometabolic risk. These observations have prompted proposals for a broader cardio–reno–hepato–metabolic axis. However, MASLD is not currently included in the established cardiovascular-kidney-metabolic (CKM) definition or staging system, and its incorporation remains an evolving conceptual extension. Prediabetes is a reversible condition characterized by abnormal glucose levels that do not meet the diagnostic criteria for diabetes. The American Diabetes Association defines prediabetes as glycated hemoglobin (HbA1c) = 5.7–6.4%, fasting plasma glucose = 100–125 mg/dL, or two-hour plasma glucose during an oral glucose tolerance test = 140–199 mg/dL. This comprehensive review examines traditional and genetic risk determinants, shared pathophysiological mechanisms, diagnostic strategies, clinical manifestations, emerging phenotypes, circulating microRNAs as non-invasive biomarkers, complications, and the principal therapeutic strategies, including diet, exercise, and pharmacotherapy. Particular attention is given to the recent approvals of resmetirom and semaglutide for metabolic dysfunction-associated steatohepatitis and to the expanding roles of sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and non-steroidal mineralocorticoid receptor antagonists. Cardiovascular, renal, metabolic, and hepatic disorders are frequently present in the same patient. Other individuals may develop this high-risk cluster over time. The aim of this article is to define the interplay between different metabolic conditions and to outline the best approach to diagnosis, monitoring, and effective integrated therapy.

27 October 2026 in Epidemiologia
Verified
Journal Article
Open access
PDF file
NANechita Alexandru
Nechita Alexandru
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
Mara DiaconuMara Diaconu
Mara Diaconu
BMBogdan Marcu
Bogdan Marcu
VEVasilica Enache
Vasilica Enache
Cardiovascular disease (CVD) is the most important contributor to global mortality and disability, and its aetiology extends well beyond the classical behavioural and metabolic risk factors. This exploratory narrative review examines selected international evidence on air and water pollution, geological and urban exposures, socioeconomic disadvantage, and working conditions in mining, metallurgy, automotive manufacturing, agriculture and sedentary or psychosocially demanding occupations. Central and Eastern Europe, including Romania, is considered as a contextual example rather than a separately studied population. We also sought to describe the mechanisms through which specific risk factors trigger harmful pathophysiological responses. Associations differ by exposure definition, outcome, study design and source population. The review identifies prevention and research priorities while acknowledging its purposive evidence selection, heterogeneous populations and lack of a systematic search or new pooled analysis. Population-specific longitudinal and intervention studies are needed to quantify joint effects and the cardiovascular benefits of structural prevention.

13 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Dan Cristian PopescuDan Cristian Popescu
Dan Cristian Popescu
Mara DiaconuMara Diaconu
Mara Diaconu
NANechita Alexandru
Nechita Alexandru
Cardiovascular diseases, particularly atherosclerotic coronary artery disease (CAD), remain among the leading causes of mortality worldwide. Although traditional risk factors—such as arterial hypertension, dyslipidemia, diabetes mellitus, obesity, smoking, and physical inactivity—are well established, accumulating evidence highlights the significant role of psychosocial factors in modulating cardiovascular risk. Among these, occupational stress—conceptualized through models such as job strain (high job demands combined with low control) and effort–reward imbalance—has been consistently associated with an increased risk of coronary events. The interaction between occupational stress and classical cardiovascular risk factors remains insufficiently elucidated and challenging to quantify. This review examines the current scientific evidence regarding the relationship between occupational stress and CAD, synthesizing findings from major epidemiological studies and relevant meta-analyses. Chronic exposure to work-related stress activates neuroendocrine pathways, including the hypothalamic–pituitary–adrenal axis and the sympathetic nervous system, promotes a state of low-grade systemic inflammation, and facilitates the adoption of unhealthy behaviors such as smoking, poor dietary habits, physical inactivity, and excessive alcohol consumption. These mechanisms contribute to endothelial dysfunction, hypercoagulability, and acceleration of the atherosclerotic process. Landmark investigations, including the INTERHEART study, meta-analyses conducted by Kivimäki and colleagues, and prospective studies by Chandola on the metabolic syndrome, support both the cumulative and independent impact of occupational stress on cardiovascular risk. Although the proportion of risk attributable to occupational stress is lower than that associated with traditional risk factors, its modifiable nature underscores a substantial potential for targeted preventive interventions. Strategies aimed at reducing occupational stress encompass individual-level approaches (stress management programs, lifestyle modification, psychological support), organizational interventions (optimizing the balance between job demands and employee control, enhancing social support in the workplace), and public health policies (occupational health promotion programs, regulatory measures addressing work-related stress, and screening for occupational stress). Recognizing occupational stress as a modifiable risk factor for CAD has important implications for both clinical practice and public health. Future research should focus on large-scale longitudinal studies, the identification of stress-related biomarkers, and the cost-effectiveness of stress-reduction interventions in the prevention and management of coronary artery disease.